Articles From: IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma to Gendis Inc. Announces Third Quarter Results


2014/12/6
- Note: This press release corresponds to abstract 31.
Sign-up for IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA ® (pembrolizumab), the company’s anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82), in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after treatment with brentuximab vedotin.
Sign-up for Data Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting investment picks
78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle Results to be Presented During an Oral Session at the American Society of Hematology (ASH) 56th Annual Meeting and Exposition on Monday, December 8 at 10:30 a.m. PT Data to be Featured in ASH Press Briefing on Saturday, December 6 at 10 a.m. PT THOUSAND OAKS, Calif.
Sign-up for Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease investment picks
http://media.marketwire.com/attachments/201211/99925_41732_threshold.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163477&ProfileId=051205&sourceType=1 SAN FRANCISCO, CA --
Sign-up for Encouraging Initial Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bortezomib (Velcade(R)) Plus Dexamethasone ("TBorD") in Patients With Relapsed/Refractory Multiple Myeloma Presented at ASH Annual Meeting investment picks
-Profile Supports Potential Role in Modulating Tumor Microenvironment in Blood-Related Cancers, Including AML, MDS, CMML and CLL- -Analysis Also Provides Scientific Basis for Pacritinib's Lack of Myelosuppression, a Unique Attribute Among Agents in Development for Myelofibrosis- SEATTLE , Dec.
Sign-up for CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers investment picks
CBS Corp (CBS) and Dish Network (DISH) reached an multi-year agreement on Saturday, ending a dispute that led to a short programming blackout on Friday night.
Sign-up for CBS and Dish settle fee dispute investment picks
2014/12/6
By Amy Hoak, MarketWatch 'Smart home' gadgets become more affordable and more common Homeowners are increasingly looking to technology for home security solutions, to save on heating and cooling costs and even to help them cook the perfect steak.
Sign-up for UPDATE: 5 tech gadgets you need in your home today investment picks
2014/12/6
Chipotle's Arnold says the chain has "a culture where employees are trained to make what they can with the ingredients we have if a customer asks." In other words, go ahead and enjoy your Quesarito.
Sign-up for UPDATE: 10 things Chipotle won't tell you -2- investment picks
2014/12/6
By Catey Hill, MarketWatch On special today: Old produce, big markups and hygiene problems 1.
Sign-up for UPDATE: 10 things grocery stores won't tell you investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001). The data from the AETHERA trial were featured at the 56th American Society of Hematology (ASH) Annual Meeting press program today and will be presented in an oral session on December 8, 2014.
Sign-up for Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting investment picks
Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition Overall Response Rate, Duration of Response, Health-Related Quality of Life Secondary Endpoints Met; Overall Survival Continues to be Monitored Results to be Presented During an Oral Session at ASH on Sunday, December 7 at 12 p.m. PT Data to be Featured in ASH Press Briefing on Saturday, December 6 at 8 a.m. PT THOUSAND OAKS, Calif.
Sign-up for Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma investment picks
http://media.marketwire.com/attachments/201211/54409_Methodelogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163486&ProfileId=051205&sourceType=1 CHICAGO, IL --
Sign-up for Methode Electronics' Board Approves Dividend investment picks
CBS Corporation (NYSE: CBS.A and CBS) and DISH Network L.L.C., a wholly owned subsidiary of DISH Network Corporation (NASDAQ: DISH), have reached a multi-year agreement for carriage of CBS owned stations across the country, as well as CBS Sports Network, Smithsonian Channel, TVGN and Showtime Networks, which includes Showtime TV Everywhere and Video-on-Demand rights.
Sign-up for CBS and DISH Reach Content Carriage Agreement investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0982922001&sourceType=1 http://media3.marketwire.com/logos/20141006-div_logo.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Diversified Royalty Corp. Provides Update on Advancement of Legal Fees for John Bennett investment picks
SAN DIEGO and ANKENY, Iowa , Dec.
Sign-up for Robbins Arroyo LLP Is Investigating the Officers and Directors of Casey's General Stores, Inc. (CASY) on Behalf of Shareholders investment picks
The Rosen Law Firm announces that it is investigating the Board of Directors of Actuate Corporation (NASDAQ: BIRT) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Actuate Corporation to maximize shareholder value before agreeing to be acquired by OpenText Corporation (NASDAQ: OTEX). If you would like to join the action, go to http://rosenlegal.com/cases-457.html or contact Phillip Kim or Kevin Chan, toll-free at 866-767-3653, or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com .
Sign-up for EQUITY ALERT: The Rosen Law Firm Announces Investigation of Actuate Corporation Concerning its Proposed Sale to OpenText investment picks
SANTA MONICA, Calif.
Sign-up for Douglas Emmett Increases Quarterly Cash Dividend investment picks
SAN FRANCISCO , Dec.
Sign-up for Prologis Declares Quarterly Dividends investment picks
2014/12/5
VANCOUVER , Dec.
Sign-up for Ritchie Bros. Auctioneers Publishes Monthly Auction Metrics investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0982878001&sourceType=1 http://www.ccnmatthews.com/logos/20110928-brok.jpg http://www.ccnmatthews.com/logos/20110928-brok.jpg http://www.ccnmatthews.com/logos/20071005-hsm.jpg http://media3.marketwire.com/docs/bkfld200.jpg NEW YORK, NEW YORK --
Sign-up for Brookfield Funds' Monthly and Special Distribution Declarations investment picks
http://media.marketwire.com/attachments/201109/32868_SigmaDesigns_logo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163454&ProfileId=051205&sourceType=1 MILPITAS, CA --
Sign-up for Sigma Designs, Inc. Schedules Conference Call to Review Third Quarter of Fiscal Year '15 Financial Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G027942-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/12/5/11G027942/Gendis_logo-574489985934.JPG WINNIPEG, MB--(Marketwired - December 05, 2014) - Gendis Inc. (TSX: GDS) today announced its financial results for the 3rd quarter ended October 31, 2014.
Sign-up for Gendis Inc. Announces Third Quarter Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma to Gendis Inc. Announces Third Quarter Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent